ERS Vision – Live Panel Discussion

Impact of COVID-19 on ILD

7 December, 2021 | Online

18:00–19:00 CEST


Registration is open for the next edition of ERS Vision Live – our live panel discussion series hosted on the ERS Respiratory Channel. The event will focus on the impact of COVID-19 on interstitial lung disease.

Expert panellists will discuss the fibrotic progression after COVID-19 and the home tele-monitoring process of patients with interstitial lung disease.

The organisation of services to monitor and support patients with long COVID will also be addressed throughout this live discussion.

The event is completely free to access but registration is required.


Sara Tomassetti - profile image
Sara Tomassetti

Sara Tomassetti is currently an Associate Professor of Respiratory Medicine at Florence University, Italy, and Head of Interventional Pulmonology Unit at Careggi University Hospital, Florence, Italy. She has extensive experience in all aspects of interstitial lung diseases and interventional pulmonology, including cryobiopsy. In addition to this, she is a faculty member of the European Respiratory Society, and BOND National member for Italy of the European Association for Bronchology and Interventional Pulmonology. From a clinical research perspective, she has been the primary investigator (PI) of several sponsored and investigator initiated clinical trials on diagnosis and treatment of interstitial lung diseases and idiopathic pulmonary fibrosis.

Carlos Robalo Cordeiro - profile image
Carlos Robalo Cordeiro

Prof. Carlos Robalo Cordeiro is the Head of Pulmonology Department at the Coimbra University Hospital and Dean of Coimbra Medical School where he is a Professor of Pulmonology. He was President of the Portuguese Society of Pulmonology, Executive Committee member of the WASOG – World Association of Sarcoidosis and Other Granulomatosis and Secretary General of the European Respiratory Society. He was also elected in August 2020 for the ERS presidential cycle (President Elect 2021/2022). Interstitial Lung Disease is his main field of interest, having published 130 papers in impact factor journals and peer reviewed 16 national and international journals and been a board member of 8 national and international journals.


Marlies Wijsenbeek - profile image
Marlies Wijsenbeek

Prof. Marlies Wijsenbeek is a chair of the Erasmus MC multidisciplinary Centre of Interstitial Lung Diseases and Sarcoidosis (ILDS), a national expert centre and member of the European Reference Network based at the Erasmus University Medical Centre, Netherlands. Her research interests include patient-centred outcome measures in ILDS, e-health and new therapies in pulmonary fibrosis and sarcoidosis. She is also chair of the ERS Group 12.01 and associate editor of the European Respiratory Journal.

Katerina Antoniou - profile image
Katerina Antoniou

Katerina Antoniou is an associate Professor of Respiratory Medicine and Head of Lab. of Cellular and Molecular Pulmonology, University of Crete. She has been actively involved in the European Respiratory Society and currently serves as Head of the Assembly 12- Interstitial Lung Diseases. Assoc. Prof. Antoniou has been awarded with an ERS Research Fellowship, which she undertook in the ILD Unit of Royal Brompton Hospital, London. Her primary research goals are focused on deciphering the role of alveolar macrophages in Interstitial Lung Diseases.

David Montani - profile image
David Montani

David Montani is a Professor at the French National Referral Centre for Pulmonary Hypertension, in the Department of Respiratory Medicine, headed by Pres. Marc Humbert at the Hôpital Bicêtre, Le Kremlin-Bicêtre, Paris-Saclay University, France. His main research interest is in the field of pulmonary vascular diseases, particularly in the management of pulmonary veno-occlusive disease (PVOD), pulmonary arterial hypertension (PAH) associated with drug exposure, PAH associated with orphan pulmonary diseases and genetics (BMPR2, ACVRL1, NF1) of PAH and PVOD. In addition to this, he is involved in laboratory-based research in the INSERM U999 laboratory « Pulmonary Hypertension: Pathophysiology and Novel Therapies» headed by Pres. M. Humbert, Hôpital Marie Lannelongue, Le Plessis Robinson.